title: [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].
abstract: The intravenous immunoglobulin infusion therapy (IVIg) has recently acquired an important role in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Some patients, however, require repetitive infusions to maintain the improvement. We planned a one-day therapy with 0.4 g/kg of IVIg in every 7 or 10 days for two CIDP patients who had required a 5-day course of IVIg in every month because of frequent exacerbations. Serum levels of IgG in both patients were kept as high as 2,000 mg/dl resulting in maintaining the improvement without any side effects.
authors.affiliation: Neurology, Kobe University Hospital.
authors.forename: Fumio
authors.initials: F
authors.lastname: Kanda
authors.forename: Kenji
authors.initials: K
authors.lastname: Sekiguchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Oishi
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Hamaguchi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Mitsui
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kobessho
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Higuchi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Shirafuji
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishihara
mesh_terms: D004334:Drug Administration Schedule; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000628:therapy*; D055502:Secondary Prevention
chemical_list: D016756:Immunoglobulins, Intravenous